Showing 1 - 1 of 1 Heart Attack (Myocardial Infarction)
HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

Status: Open Not Enrolling

Investigator: Mahwash Kassi

Study Coordinator: Jan-Michael Ragunton

Phone: 713.441.9837

This study will evaluate the efficacy and safety of vutrisiran 25 mg administered subcutaneously (SC) once every 3 months (q3M) compared to placebo in patients with ATTR amyloidosis with cardiomyopathy. ... Read more >